OpenAI buys Orchestra Bio as 8VC reveals it led the Series A

OpenAI has acquired Orchestra Bio, and the write-ups of the deal all put the startup’s funding at about $20 million without saying what kind. The one investor that published a post on it is more specific. 8VC says it led Orchestra Bio’s Series A last year, a round and a lead that TechCrunch, SiliconANGLE and Decrypt all leave out.

The acquisition was announced on Tuesday 20 October. Orchestra’s team and technology go into Rosalind, OpenAI’s family of life sciences models, and into Rosalind Workbench, the harness meant to help researchers plan experiments and analyse results, TechCrunch reported. Terms weren’t disclosed, and OpenAI gave no date for when Orchestra’s agents land in its products.

Because no price was given, the $20 million raise is the only money figure in the story, which is why the labelling matters. No two accounts of it agree. When a company announces a round itself the stage and the lead are on the record, as they were for Snorkel’s $350M Series E, but Orchestra’s August 2025 launch gave a total instead.

Source	How the money is described	Investors named
8VC (lead investor)	A seed raise, then a Series A led by 8VC “last year”	8VC
TechCrunch	“around $20 million as of 2025”	Andreessen Horowitz, Atria, 8VC
SiliconANGLE	Backing “at that point” came to $20 million	Andreessen Horowitz, 8VC, Insight Venture Management
Decrypt	Seed round, about $20 million in total, per Caplight data	Andreessen Horowitz, Definition Capital, Insight Partners, 8VC

8VC’s post says the firm first met chief executive Ashoka Rajendra during Orchestra Bio’s seed raise, and that it then led the Series A. So there were two rounds rather than one, if the lead investor’s own account holds. That post also names an executive the coverage skipped, CTO Andy Xu.

What Orchestra sells is coordination rather than science. Its agents handle the minutiae of drug-discovery operations, from tracking finances to resolving clinical trial scheduling problems, TechCrunch said. When a manufacturing batch fails, the software works out which activities and timelines take the hit and weighs ways to respond, though people still make the final call.

8VC also puts numbers on the risk that OpenAI just bought into. Roughly nine in ten drug candidates entering clinical trials never reach approval, the firm says, and a single Phase III failure can cost between $800 million and $2.4 billion. Those odds are why thin early readouts draw so much attention, including the 2-of-3 glaucoma result we covered this month.

AI has now reached an inflection point where people and agents can take this on together.

Orchestra Bio, in the notice on its own site

Rosalind is six months old. It started in April as GPT-Rosalind, a reasoning model for biology and drug discovery research, and eligible organisations have been able to use it outside research preview since September under a trusted-access program, SiliconANGLE reported. Moderna and Novo Nordisk are among the drugmakers already working with OpenAI on it. By the company’s own count, getting a new medicine through to US approval takes 10 to 15 years on average.

The rivalry is the backdrop here. Anthropic bought AI biotech startup Coefficient Bio for roughly $400 million in April, a figure SiliconANGLE and Decrypt both report, and Decrypt puts the cost of bringing one approved drug to market at more than $2.6 billion. OpenAI also bought medical records company Torch Health in January to build out ChatGPT Health, so this is not its first health deal of the year, and its science push has had setbacks of its own.

Watch who gets the agents first. OpenAI hasn’t put a date on the integration and Rosalind still sits behind trusted access, so the near-term test isn’t the technology. TechCrunch framed it as the fear that labs become competitors to the startups building on them, and here one of those startups got absorbed instead.